Suvanza Pharma, LLC (SUVZ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.01M is the value of all shares combined. Beta 2.36: the stock has moved about 136% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSuvanza Pharma, LLC (SUVZ) trades at $0.0002. Suvanza Pharma, LLC is an early-stage biotechnology company focused on developing the RapiDerm skin drug delivery system for dermatological diseases. Market cap: $1.01M, Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SUVZ: SUVZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Suvanza Pharma, LLC (SUVZ) Healthcare & Pipeline Overview
Suvanza Pharma, LLC, an early-stage biotechnology firm, is focused on the development of its RapiDerm skin drug delivery system for dermatologic diseases. Operating in the competitive biotechnology sector, Suvanza aims to innovate drug delivery for skin conditions, but currently has a $0 market cap.
What Is the Investment Thesis for SUVZ?
Suvanza Pharma, LLC presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The core value driver is the RapiDerm drug delivery system, which, if successful in clinical trials, could revolutionize the treatment of dermatological diseases. However, with a market capitalization of $1.01M as of March 2026, the company's valuation is entirely dependent on future prospects. Key growth catalysts include positive clinical trial results for RapiDerm, potential partnerships with larger pharmaceutical companies, and successful navigation of the FDA approval process. Investment risks include the inherent uncertainty of drug development, the need for substantial further funding, and competition from established players in the dermatology market. The company's beta of 2.36 indicates high volatility, reflecting the speculative nature of its stock.
Based on FMP financials and quantitative analysis
SUVZ Key Highlights
Suvanza Pharma, LLC operates as an early-stage biotechnology company focused on dermatological drug delivery systems.
- The company's primary asset is the RapiDerm technology, a novel skin drug delivery system.
- Founded in 2004, Suvanza Pharma has been developing its technology for over two decades.
- The company has a market capitalization of $1.01M, reflecting its pre-revenue status.
- Suvanza Pharma's stock exhibits high volatility, with a beta of 2.36.
Who Are SUVZ's Competitors?
SUVZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ELVAY Evolva Holding S.A. | $1.16 | 0.00% | — | |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 68 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SUVZ's Key Strengths?
Proprietary RapiDerm drug delivery system.
- Focus on a specific market niche (dermatology).
- Potential for improved drug efficacy and patient compliance.
- Experienced leadership team.
What Are SUVZ's Weaknesses?
Early-stage company with no current revenue.
- Dependence on successful clinical trials and regulatory approvals.
- Limited financial resources.
- High reliance on a single technology (RapiDerm).
What Are the Key Risks for SUVZ?
Failure to obtain regulatory approvals for the RapiDerm system could halt development and commercialization efforts.
- Unsuccessful clinical trials could undermine the value of the RapiDerm technology.
- Competition from established pharmaceutical companies with greater resources and market share.
- Dependence on securing additional funding to support ongoing research and development activities.
- Intellectual property risks, including patent infringement or challenges to existing patents.
What Are SUVZ's Competitive Advantages?
- Proprietary RapiDerm technology: The patented skin drug delivery system provides a unique competitive advantage.
- Potential for improved drug delivery: RapiDerm may offer enhanced efficacy and patient compliance compared to traditional methods.
- Focus on dermatological diseases: Specialization allows for targeted research and development efforts.
- First-mover advantage: As an early-stage company, Suvanza has the potential to establish a leading position in the market.
What Does SUVZ Do?
Suvanza Pharma, LLC, established in 2004 and based in Miami Beach, Florida, is a biotechnology company specializing in the development of innovative drug delivery systems for dermatological applications. Originally known as Hamilton PNG, the company rebranded to Suvanza Pharma in March 2010, marking a strategic shift towards its current focus. Their primary focus is the RapiDerm system, a novel skin drug delivery technology designed to improve the treatment of various skin diseases. As an early-stage company, Suvanza Pharma is currently in the development phase and does not yet have products on the market. The company's strategy revolves around advancing RapiDerm through preclinical and clinical trials, seeking partnerships, and eventually commercializing the technology. Suvanza operates within the broader biotechnology industry, specifically targeting the dermatology segment. The company's success hinges on the efficacy and market acceptance of RapiDerm, as well as its ability to secure funding and navigate the regulatory landscape.
What Products and Services Does SUVZ Offer?
- Develops the RapiDerm skin drug delivery system.
- Focuses on treatments for dermatologic diseases.
- Conducts research and development activities.
- Seeks to improve drug delivery through innovative technology.
- Aims to commercialize RapiDerm for clinical use.
- Operates as an early-stage biotechnology company.
How Does SUVZ Make Money?
- Develops and patents the RapiDerm drug delivery system.
- Outlicenses or partners with pharmaceutical companies for commercialization.
- Generates revenue through licensing fees and royalties.
- Potentially manufactures and sells RapiDerm products directly, pending regulatory approval.
What Industry Does SUVZ Operate In?
Suvanza Pharma operates within the biotechnology industry, specifically targeting the dermatology market. This market is characterized by increasing demand for advanced treatments for skin diseases, driven by an aging population and rising awareness of skin health. The competitive landscape includes established pharmaceutical companies, as well as other biotechnology firms developing novel dermatological therapies and drug delivery systems. However, the industry is also highly regulated, requiring extensive clinical trials and regulatory approvals before products can be commercialized.
Who Are SUVZ's Key Customers?
- Pharmaceutical companies seeking innovative drug delivery technologies.
- Dermatologists and other healthcare professionals treating skin diseases.
- Patients suffering from dermatological conditions.
- Potential future customers include hospitals and clinics.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Suvanza Pharma, LLC operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Nardo Zaias. SUVZ has traded publicly since 1995.
SUVZ Latest News
No recent news available for SUVZ.
SUVZ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SUVZ.
Price Targets
Wall Street price target analysis for SUVZ.
SUVZ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SUVZ; grades run from A+ (80-100) to F (below 30).
Leadership: Nardo Zaias
CEO
Nardo Zaias serves as the CEO of Suvanza Pharma, LLC. Further research would be required to provide a comprehensive background profile, including his credentials and expertise in the biotechnology or pharmaceutical industry.
Track Record: Due to the limited information available, Nardo Zaias's track record at Suvanza Pharma, LLC cannot be accurately assessed. Key achievements, strategic decisions, and company milestones under his leadership are currently unknown. Further data is needed to evaluate his performance and contributions to the company's development.
SUVZ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Suvanza Pharma may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal revenue, or may be undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. Information availability is often limited, making it difficult to assess the company's financial health and prospects. This tier is also known for attracting shell companies and potentially fraudulent schemes, requiring investors to exercise extreme caution.
- OTC Tier: OTC Other
- Limited information and disclosure: The OTC Other tier often lacks sufficient financial disclosures, making it difficult to assess the company's true financial health.
- Low liquidity: Limited trading volume and wide bid-ask spreads can make it challenging to buy or sell shares at desired prices.
- Potential for fraud or manipulation: The OTC market is more susceptible to scams and price manipulation due to less stringent regulatory oversight.
- Going concern risk: Companies in the OTC Other tier may be facing financial difficulties and have a higher risk of bankruptcy.
- Volatility: OTC stocks can experience significant price swings due to speculative trading and limited investor interest.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements, even if unaudited.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor before investing.
- Be wary of any unsolicited investment offers or guarantees of high returns.
- Longevity of operations: The company has been in operation since 2004.
- Focus on drug development: Suvanza Pharma is engaged in research and development activities.
- Development of RapiDerm technology: The company has a specific product focus.
- Headquarters in Miami Beach, Florida: A physical presence suggests some level of operational substance.
Common Questions About SUVZ (Healthcare)
What are the main risks for SUVZ?
Suvanza Pharma, LLC faces significant risks inherent to early-stage biotechnology companies. The success of the company is heavily reliant on the clinical trial outcomes of the RapiDerm system.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Suvanza Pharma, LLC due to its OTC Other tier status and lack of public disclosures.